Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15212 ↗At a glance
Randomisierte kontrollierte Studie in ESC Heart Failure, 2025. Written by Shodai Kawanami and 11 co-authors. Institution: Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan. Major MEDLINE topics: Heart Failure, Glucosides, Benzhydryl Compounds, Stroke Volume. Cited 6 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0).
Topics: Herzinsuffizienz
Abstract (original language)
Aims
Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone. Methods and results We enrolled 114 consecutive acute decompensated heart failure (ADHF) patients with a left ventricular ejection fraction (LVEF) of less than 50%. The patients were prospectively randomized to be assigned either to DAPA group who received DAPA at a dose of 10 mg once daily within 24 h after admission or conventional therapy group (CON group) who received loop diuretics alone. All patients were adjusted by increasing or decreasing the loop diuretic by 10 mg to maintain a 1–2 mL/kg/h urine output. The primary endpoint was the incidence of WRF, which was defined as an increase in the serum creatinine of ≥0.3 mg/dL from baseline. The median age of the patients was 77 [interquartile range (IQR): 64, 85] years, 35% were female and the median LVEF was 33 [IQR: 28, 38] %. There was no significant difference in the incidence of WRF between the two groups (16.1%, n = 9 vs. 12.1%, n = 7, P value = 0.54). The total dose of loop diuretics through day 7 was lower in the DAPA group than CON group (184 ± 79.5 mg vs. 214 ± 66.5 mg, P value = 0.03).
Conclusions
This randomized prospective trial revealed the addition of DAPA within 24 h after admission reduced the diuretic dose without WRF.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan.
ORCID profiles: Masami Nishino
Cite
APA
Kawanami, S., Egami, Y., Abe, M., Osuga, M., Nohara, H., Ukita, K., Kawamura, A., Yasumoto, K., Okamoto, N., Matsunaga-Lee, Y., Yano, M., & Nishino, M. (2025). Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.15212
Vancouver
Kawanami S, Egami Y, Abe M, Osuga M, Nohara H, Ukita K, et al. Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure. ESC Heart Failure. 2025. doi:10.1002/ehf2.15212
BibTeX
@article{Kawanami2025,
author = {Kawanami, Shodai and Egami, Yasuyuki and Abe, Masaru and Osuga, Mizuki and Nohara, Hiroaki and Ukita, Kohei and Kawamura, Akito and Yasumoto, Koji and Okamoto, Naotaka and Matsunaga-Lee, Yasuharu and Yano, Masamichi and Nishino, Masami},
title = {Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15212}
}
EUVIMED